Loren Data's SAM Daily™

FBO DAILY ISSUE OF FEBRUARY 15, 2002 FBO #0075
SOLICITATION NOTICE

A -- Genotyping services

Notice Date

2/13/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

RFQ-NCI-20019-NG
 

Response Due

2/20/2002
 

Archive Date

3/7/2002
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

mh139x@nih.gov, rasmusc@mail.nih.gov
 

Description

The National Cancer Institute (NCI), Center for Cancer Research (CCR), Cancer Prevention Studies Branch (CPSB), plans to procure continuous genotyping services from BioServe Biotechnologies, LTD, 1050 West Street, Laurel Maryland. This procurement will provide for continuation of research studies previously awarded under NCI purchase order 263 MQ109475. The CPSB conducts intramural research in the areas of genetics and cancer, nutrition and cancer, chemoprevention and other prevention strategies aimed at lowering human cancer risk. The purpose of this procurement is to obtain data on polymorphisms from DNA collected from prostate, pancreatic, and gastrointestinal cancer cases, non-cases, and quality control samples in order to understand the role of these enzyme polymorphisms in the etiology of cancer. The contractor shalll be required to perform the following: 1) provide results of enzyme genotype analyses as a Microsoft excel file, 2) conduct studies on eight previously developed genotype assays on either gastrointestinal/pancreatic or prostate cancer case-control studies. The contractor shall develop genotype assays on 10 new studies and perform assays, 3) contractor shall provide a report on the method to be used for each genotyping assay, A report (along with the Microsoft Excel file data with the genotypes characterized as homozygous dominant, heterozygous, or homozygous recessive coded as 0, 1, and 2, respectively) shall be provided to the NCI and include all 20 genotypes analyses. The polymorphisms to be genotype assayed are MnSOD, CYP3A4, CYP1A2, NAT1, Estrogen Receptor, TGF-alpha, p53, Leptin R, IGF-1, IGFBP-3, IGF-2, Endostatin, Endothelin, Cyclin D, PPAR-gamma, Tryosinase, Melanocortin Receptor, Vitamin D Receptor, Glucocorticoid Receptor, and Hormone-sensitive lipase. The assay development work for several of these polymorphisms have already been performed by BioServe Biotechnology, Inc. The enzyme polymorphism assays were developed by BioServe in conjunction with investigators within the CPSB for pursuing their role in the development of esophageal cancer in another CPSB-based cohort study conducted in China. The current acquisition is based on results of the earlier mass throughput developmental work and optimization of the ABI Prizm 7700 genotyping techniques (TAQMAN) and Matrix Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF) technology. These approaches have provided extremely accurate and reproducible results, with 100% concordance rates in all blinded control samples analyzed thus far. BioServe Biotechnology has established expertise and is reknown in the assay of genetic polymoprhisms. There is a need to continue the work with BioServe Biotechnologies for comparability of data. To introduce another company would be detrimental to this research work. BioServe Biotechnologies is the only source known to the NCI researcher that has most of the polymorphism assays currently running with expertise in the mass throughput Taqman and MALDI-TOF techniques which yields 100% reproducibility rate. This notice of intent is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 1:00 PM EST, on February 20, 2002. For further information please contact Malinda Holdcraft, Purchasing Agent (301)-402-4509. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD

Zip Code: 20892

Country: USA
 

Record

SN00026097-W 20020215/020213213102 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |